Pricing Log in Create free account

AN2 Therapeutics, Inc. (ANTX) vs Nkarta, Inc. (NKTX)

AN2 Therapeutics, Inc. and Nkarta, Inc. are both Biotechnology companies. AN2 Therapeutics, Inc. and Nkarta, Inc. are of similar size ($138.2M and $135.9M). Across the 9 metrics below, AN2 Therapeutics, Inc. leads on 6 and Nkarta, Inc. on 3.

Valuation

Metric ANTX NKTX Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 1.99 0.54 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.39 0.64
EV/Sales n/m n/m 9.21
Earnings yield (31.66%) (87.22%) (33.15%)
Free cash flow yield (20.28%) (70.03%) (25.50%)

Profitability

Metric ANTX NKTX Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (50.12%) (38.76%) (56.36%)
Return on assets (46.06%) (29.86%) (48.04%)
Return on invested capital 0.00% (127.22%) 0.00%

Growth

Metric ANTX NKTX Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 32.56% 11.88% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ANTX NKTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.32 7.98 4.72
Net debt to EBITDA 1.48 2.35 0.96

Dividend

Metric ANTX NKTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ANTX NKTX Biotechnology median
Market cap 135.85m 138.24m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack